GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
| Revenue (TTM) | $33.20B |
| Gross Profit (TTM) | $24.40B |
| EBITDA | $10.82B |
| Operating Margin | 30.90% |
| Return on Equity | 33.40% |
| Return on Assets | 10.00% |
| Revenue/Share (TTM) | $16.51 |
| Book Value | $11.93 |
| Price-to-Book | 4.27 |
| Price-to-Sales (TTM) | 3.01 |
| EV/Revenue | 2.708 |
| EV/EBITDA | 9.29 |
| Quarterly Earnings Growth (YoY) | -69.50% |
| Quarterly Revenue Growth (YoY) | 5.30% |
| Shares Outstanding | $2.00B |
| Float | $1.94B |
| % Insiders | 0.06% |
| % Institutions | 17.49% |
Volatility is currently contracting
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expanding oncology pipeline.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than currently approved standard- and high-dose shots.
H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN study results. By the way, Hibsago [bepirovirsen] was approved by Japan's Ministry of Health, Labour, and Welfare on August 24.
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GSK and any ticker you trade — then tracks every position and per-strategy win rate.
